시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 의약품 리포지셔닝 서비스 시장 보고서(2025년)
Drug Repositioning Service Global Market Report 2025
상품코드 : 1877626
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,675,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,648,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,622,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

의약품 리포지셔닝 서비스 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2024년 323억 4,000만 달러에서 2025년에는 342억 달러에 달할 것으로 추정되며, CAGR 5.7%로 확대될 전망입니다. 이 역사적인 기간 동안의 성장은 기존의 의약품 개발에 있어서 높은 실패율, 희소질환용 의약품 지정 및 패스트트랙 승인 등 규제 상의 우대 조치, 계산 생물학 및 AI의 진보, 헬스케어 비용 증가, 기존 의약품으로부터 풍부한 임상 데이터의 이용가능성에 의해 견인되고 있습니다.

의약품 리포지셔닝 서비스 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 432억 6,000만 달러에 달할 것으로 예측되며, CAGR 6.1%로 성장할 전망입니다. 예측 기간의 성장 요인으로는 만성 질환 및 복잡 질환의 유병률 증가, AI 및 머신러닝의 지속적인 진보, 맞춤형 의료에 대한 주목 증가, 세계적인 헬스케어 액세스의 확대, 재이용약의 지적재산 보호 강화, 제약기업과 연구기관 간의 연계 강화 등을 들 수 있습니다. 예측 기간의 주요 동향으로는 비용 효율적인 의약품 개발에 대한 수요 증가, 데이터 구동형 재이용 플랫폼 확대, 희귀질환 및 복잡 질환에 대한 주력, 주요 지역에서의 꾸준한 시장 성장, 재배치 전략에 대한 규제 면의 지원, 예측 분석 및 실세계 데이터 통합에 대한 투자 증가 등을 들 수 있습니다.

헬스케어 지출 증가는 향후 의약품 리포지셔닝 서비스 시장의 성장에 기여할 것으로 예측됩니다. 헬스케어 지출은 예방, 치료, 재활 및 관리를 포함한 의료 서비스에 할당되는 총 자금을 의미합니다. 헬스케어 지출 증가는 기술 진보로 인한 의료비 상승과 의료 서비스 수요 증가로 인한 것입니다. 헬스케어 지출 증가는 임상시험 및 조사에 대한 자금 제공을 확대함으로써 의약품 리포지셔닝 서비스를 지원하고 기존 약물의 신규 치료 용도의 발견을 가속화합니다. 예를 들어 2022년 3월 미국 연방기관인 메디케어 메디케이드 서비스센터가 발표한 '2021-2030년 국가 의료 지출 보고서'에 따르면 2021-2030년 연간 평균 의료비 증가율은 5.1%로 예측되며, 총액은 약 6조 8,000억 달러에 이를 전망입니다. 게다가 동기간에 메디케어 지출은 연률 7.2%로 증가하고, 메디케이드 지출은 5.6%의 성장률이 전망되고 있습니다. 그러므로 헬스케어 비용 증가는 의약품 전용 서비스 시장의 성장을 지원합니다.

의약품 리포지셔닝 서비스 시장의 주요 기업은 기존 의약품의 새로운 치료 용도를 특정하는 컴퓨터 지원 창약 리포지셔닝 시스템 등 의약품 리포지셔닝에 있어서 인공지능(AI)의 활용을 중시하고 있습니다. 이것은 과학 문헌과 생물학적 데이터를 AI 기반으로 분석하는 기법입니다. 컴퓨터 지원 창약 재배치 시스템은 인공지능, 머신러닝, 데이터 마이닝을 적용하고 기존 의약품, 화합물 및 생물학적 데이터 세트를 체계적으로 평가하는 기술 중심 플랫폼입니다. 예를 들어, 2024년 11월에는 일본 기업인 우베 코산 주식회사(UBE)와 프론테오 주식회사(FRONTEO)가 양사의 전문 지식을 조합한 협업 틀을 구축하고, 창약 재배치의 대처를 강화하는 공동 창조 프로젝트를 시작했습니다. 이 프로젝트는 건식 연구(데이터 분석)와 습식 연구(생물학적 시험)의 통합을 촉진하고 가설 구축에서 실험 검증까지의 프로세스를 개선합니다. 프론테오의 AI 구동형 '창약 AI 팩토리' 및 'KIBIT' 기술을 활용하여 질병과 분자 구조 사이에 지금까지 보고되지 않았던 관련성을 효율적으로 발견합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Drug repositioning service involves the systematic identification of new therapeutic uses for existing drugs, enabling pharmaceutical companies to maximize the value of their current drug portfolios while reducing the risks associated with developing entirely new compounds. By leveraging existing clinical data and research, these services help streamline the drug development process, significantly decreasing the time and cost required to deliver effective treatments to patients.

The primary types of drug repositioning service are generic drugs and clinical trial failed drugs. Generic drugs are medications that contain the same active ingredients, strength, dosage form, and therapeutic effect as brand-name drugs but are generally offered at lower prices. The key therapeutic areas include oncology, neurology, infectious diseases, cardiovascular diseases, and other therapeutic areas. These services are utilized by various end users such as pharmaceutical companies, biotechnology firms, contract research organizations, academic research institutions, hospitals, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The drug repositioning service market research report is one of a series of new reports from The Business Research Company that provides drug repositioning service market statistics, including drug repositioning service industry global market size, regional shares, competitors with a drug repositioning service market share, detailed drug repositioning service market segments, market trends and opportunities, and any further data you may need to thrive in the drug repositioning service industry. This drug repositioning service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug repositioning service market size has grown strongly in recent years. It will grow from $32.34 billion in 2024 to $34.2 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth during the historic period is driven by high attrition rates in traditional drug development, regulatory incentives such as orphan drug designation and fast-track approvals, advancements in computational biology and AI, rising healthcare costs, and availability of extensive clinical data from existing drugs.

The drug repositioning service market size is expected to see strong growth in the next few years. It will grow to $43.26 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be connected to increasing prevalence of chronic and complex diseases, continued advancements in AI and machine learning, growing focus on personalized medicine, expansion of global healthcare access, strengthening of intellectual property protections for repurposed drugs, collaborations between pharmaceutical companies and research institutions. Major trends in the forecast period include rising demand for cost-effective drug development, expansion of data-driven repurposing platforms, focus on rare and complex diseases, steady market growth across major regions, regulatory support for repositioning strategies, and increasing investment in predictive analytics and real-world data integration.

The rise in healthcare expenditures is expected to contribute to the growth of the drug repositioning service market going forward. Healthcare expenditures refer to the total funds allocated to health services, including prevention, treatment, rehabilitation, and administration. The increase in healthcare expenditures results from rising medical costs caused by technological advancements and the growing demand for healthcare services. Higher healthcare spending supports drug repositioning services by providing greater funding for clinical trials and research, which accelerates the discovery of new therapeutic uses for existing drugs. For instance, in March 2022, according to the 2021-2030 National Health Expenditure report published by the Centers for Medicare and Medicaid Services, a United States-based federal agency, national health spending is projected to increase by an average of 5.1 percent annually between 2021 and 2030, reaching nearly $6.8 trillion. Additionally, during the same period, Medicare spending is expected to rise at an annual rate of 7.2 percent, while Medicaid spending will grow at a rate of 5.6 percent. Therefore, the rise in healthcare expenditures is supporting the growth of the drug repositioning service market.

Leading players in the drug repositioning service market are emphasizing the use of artificial intelligence (AI) in drug repositioning, including computational drug repositioning systems that identify new therapeutic applications for existing drugs through AI-based analysis of scientific literature and biological data. A computational drug repositioning system is a technology-driven platform that applies artificial intelligence, machine learning, and data mining to systematically evaluate existing drugs, compounds, and biological datasets. For example, in November 2024, UBE and FRONTEO, two Japan-based companies, initiated a co-creation project that establishes a collaborative framework combining their expertise to strengthen drug repositioning initiatives. This project facilitates integration between dry research (data analysis) and wet research (biological testing), improving the process from hypothesis formulation to experimental verification. By utilizing FRONTEO's AI-driven Drug Discovery AI Factory and KIBIT technology, the initiative efficiently uncovers previously unreported links between diseases and molecular structures.

In January 2024, Cosmos Health Inc., a US-based healthcare group, acquired the Cloudscreen platform from Cloudpharm P.C. for an undisclosed amount. Through this acquisition, Cosmos Health Inc. aims to accelerate drug repurposing initiatives by utilizing Cloudscreen's AI platform to efficiently identify new therapeutic applications for existing drugs. Cloudpharm P.C. is a Greece-based company that provides drug repositioning services.

Major players operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

North America was the largest region in the drug repositioning service market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug repositioning service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug repositioning service market consists of revenues earned by entities by providing services such as target validation, pharmacovigilance support, formulation optimization, drug combination analysis, and post-marketing surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Repositioning Service Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug repositioning service market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for drug repositioning service ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug repositioning service market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Drug Repositioning Service Market Characteristics

3. Drug Repositioning Service Market Trends And Strategies

4. Drug Repositioning Service Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Drug Repositioning Service Growth Analysis And Strategic Analysis Framework

6. Drug Repositioning Service Market Segmentation

7. Drug Repositioning Service Market Regional And Country Analysis

8. Asia-Pacific Drug Repositioning Service Market

9. China Drug Repositioning Service Market

10. India Drug Repositioning Service Market

11. Japan Drug Repositioning Service Market

12. Australia Drug Repositioning Service Market

13. Indonesia Drug Repositioning Service Market

14. South Korea Drug Repositioning Service Market

15. Western Europe Drug Repositioning Service Market

16. UK Drug Repositioning Service Market

17. Germany Drug Repositioning Service Market

18. France Drug Repositioning Service Market

19. Italy Drug Repositioning Service Market

20. Spain Drug Repositioning Service Market

21. Eastern Europe Drug Repositioning Service Market

22. Russia Drug Repositioning Service Market

23. North America Drug Repositioning Service Market

24. USA Drug Repositioning Service Market

25. Canada Drug Repositioning Service Market

26. South America Drug Repositioning Service Market

27. Brazil Drug Repositioning Service Market

28. Middle East Drug Repositioning Service Market

29. Africa Drug Repositioning Service Market

30. Drug Repositioning Service Market Competitive Landscape And Company Profiles

31. Drug Repositioning Service Market Other Major And Innovative Companies

32. Global Drug Repositioning Service Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Repositioning Service Market

34. Recent Developments In The Drug Repositioning Service Market

35. Drug Repositioning Service Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기